Publicaciones en colaboración con investigadores/as de Universidade Federal do Rio de Janeiro (69)

2024

  1. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

    eClinicalMedicine, Vol. 71

  2. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

    Infection

  3. Phenotypic profiling of CD34+ cells by advanced flow cytometry improves diagnosis of juvenile myelomonocytic leukemia

    Haematologica, Vol. 109, Núm. 2, pp. 521-532

  4. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry

    Hematological Oncology, Vol. 42, Núm. 1

  5. T-cell immune profile in blood of systemic mastocytosis: Association with disease features

    Allergy: European Journal of Allergy and Clinical Immunology

2023

  1. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings

    International Journal of Infectious Diseases, Vol. 137, pp. 98-110

  2. Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients

    Frontiers in Oncology

  3. Lenalidomide Maintenance and Measurable Residual Disease in a Real-World Multiple Myeloma Transplanted Population Receiving Different Treatment Strategies Guided by Access to Novel Drugs in Brazil

    Cancers, Vol. 15, Núm. 5

  4. Minimal residual disease assessment in B-cell precursor acute lymphoblastic leukemia by semi-automated identification of normal hematopoietic cells: A EuroFlow study

    Cytometry Part B - Clinical Cytometry

  5. Systematic Evaluation of Antigenic Stimulation in Chronic Lymphocytic Leukemia: Humoral Immunity as Biomarkers for Disease Evolution

    Cancers, Vol. 15, Núm. 3

2022

  1. Altered innate immune profile in blood of systemic mastocytosis patients

    Clinical and Translational Allergy, Vol. 12, Núm. 6

  2. Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome

    Cancers, Vol. 14, Núm. 13

  3. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

    Blood, Vol. 140, Núm. 26, pp. 2773-2787

  4. Deciphering Biomarkers for Leptomeningeal Metastasis in Malignant Hemopathies (Lymphoma/Leukemia) Patients by Comprehensive Multipronged Proteomics Characterization of Cerebrospinal Fluid

    Cancers, Vol. 14, Núm. 2

  5. Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study

    Blood Advances, Vol. 6, Núm. 3, pp. 976-992

  6. Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study

    British Journal of Haematology, Vol. 197, Núm. 1, pp. 76-81

  7. Immunophenotypic Analysis of Acute Megakaryoblastic Leukemia: A EuroFlow Study

    Cancers, Vol. 14, Núm. 6

  8. Quality Assessment of a Large Multi-Center Flow Cytometric Dataset of Acute Myeloid Leukemia Patients—A EuroFlow Study

    Cancers, Vol. 14, Núm. 8

  9. Telomere length and Wnt/β-catenin pathway in adamantinomatous craniopharyngiomas

    European journal of endocrinology, Vol. 187, Núm. 2, pp. 219-230

  10. Unravelling soluble immune checkpoints in chronic lymphocytic leukemia: Physiological immunomodulators or immune dysfunction

    Frontiers in Immunology, Vol. 13